1-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-naphtalen-2-yl-urea | 697278-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[5-chloro-2-(1H-tetrazol-5-yl)-phenyl]-3-naphtalen-2-yl-urea
• 英文别名: 1-[5-chloro-2-(2H-tetrazol-5-yl)phenyl]-3-naphthalen-2-ylurea
• CAS: 697278-58-3
• 化学式: C₁₈H₁₃ClN₆O
• 分子量: 364.794
• InChiKey: JIMXLVJAMRAHOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Novel aryl ureido benzoic acid derivatives and their use
  申请人：Valgeirsson Jon

  公开号：US20060069255A1

  公开（公告）日：2006-03-30

  This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

  本发明涉及新型芳基脲基苯甲酸衍生物，可用作离子型GluR5受体的选择性和非竞争性拮抗剂。由于它们的生物活性，本发明的芳基脲基衍生物被认为对于治疗对天冬氨酸或谷氨酸受体调节敏感的疾病有用。此外，本发明提供了用于本发明的化学化合物，以及包含该化学化合物的药物组合物和治疗对天冬氨酸或谷氨酸受体调节敏感的疾病、障碍或状况的方法。
• ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE
  申请人：NEUROSEARCH A/S

  公开号：EP1565429A2

  公开（公告）日：2005-08-24
• US7521480B2
  申请人：——

  公开号：US7521480B2

  公开（公告）日：2009-04-21
• [EN] NOVEL ARYL UREIDO BENZOIC ACID DERIVATIVES AND THEIR USE<br/>[FR] NOUVEAUX DERIVES D'ACIDE ARYL UREIDO BENZOIQUE ET LEUR UTILISATION
  申请人：NEUROSEARCH AS

  公开号：WO2004046090A2

  公开（公告）日：2004-06-03

  This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.